Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

A 1-pot synthesis of the SARS-CoV-2 Mpro Inhibitor Nirmatrelvir, the key ingredient in Paxlovid

14 September 2022, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

A newly devised route to the Pfizer drug nirmatrelvir is reported that reduces the overall sequence to a 1-pot process and relies on a commercially available, green coupling reagent, T3P. The overall yield of the targeted material, isolated as its MTBE solvate, is 53%.

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
Optimization of reaction protocols and NMR, HRMS, and HPLC data of isolated compounds.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Sep 14, 2022 Version 1

Metrics

652
455
1
Views
Downloads

License

CC logo
CC
BY logo
BY
The content is available under CC BY 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv-2022-xz3tv
D O I: 10.26434/chemrxiv-2022-xz3tv [opens in a new tab]

Funding

Bill and Melinda Gates Foundation

Author’s competing interest statement

The author(s) have declared they have no conflict of interest with regard to this content

Ethics

The author(s) have declared ethics committee/IRB approval is not relevant to this content

Share